After FDA setback, PTC Therapeutics' DMD drug Translarna faces possible market withdrawal in Europe

A “surprised and extremely disappointed” PTC Therapeutics is scrambling to keep its Duchenne muscular dystrophy therapy Translarna on the European market after a detrimental review.